TrialBreast (Edinburgh, Scotland)2024

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study.

Alfonso Cortés et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.